RJF — Laboratorio Reig Jofre SA Balance Sheet
0.000.00%
- €243.36m
- €292.72m
- €338.90m
- 74
- 40
- 65
- 66
Annual balance sheet for Laboratorio Reig Jofre SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12.4 | 6.04 | 6.9 | 6.49 | 23 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 47.2 | 50.4 | 54.9 | 61.9 | 61 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 101 | 109 | 112 | 133 | 150 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 85.3 | 92.4 | 93.2 | 91.6 | 97 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 317 | 325 | 321 | 331 | 345 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 77.8 | 74.9 | 75.6 | 90.2 | 82.1 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 133 | 136 | 127 | 126 | 131 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 185 | 189 | 195 | 204 | 214 |
| Total Liabilities & Shareholders' Equity | 317 | 325 | 321 | 331 | 345 |
| Total Common Shares Outstanding |